Boosting nerve-cell cleanup to fight prion and Alzheimer-related brain damage

Restoring neuronal degradative capacity as a therapeutic strategy to treat Prion Disease

NIH-funded research Scripps Research Institute, the · NIH-11247516

This project boosts neurons' waste-disposal system to reduce toxic protein clumps in people with prion disease and related dementias.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionScripps Research Institute, the NIH-funded
Lab location1 site (La Jolla, United States)
Project IDNIH-11247516 on NIH RePORTER

What this research studies

Researchers are studying how nerve cells in prion disease and some Alzheimer's-related dementias build up misfolded proteins inside enlarged, poorly functioning compartments. They plan to restore lysosomal and autophagy pathways that clear these protein aggregates, testing drug and molecular approaches in lab-grown neurons and animal models. The team will measure whether boosting degradative capacity reduces protein clumps and improves axonal transport and neuronal health in these models. Any human-sample or patient-related work would be coordinated through Scripps Research and would start with biomarkers or tissue studies rather than a direct treatment right away.

Who could benefit from this research

Good fit: People diagnosed with prion disease or Alzheimer-type dementias marked by protein aggregation would be the most relevant candidates for future therapies developed from this research.

Not a fit: Patients whose conditions are not driven by protein-aggregate pathology or those with very advanced, widespread brain damage may not receive direct benefit from this project in the near term.

Why it matters

Potential benefit: If successful, this work could lower toxic protein buildup and help prevent or slow nerve-cell damage in prion disease and possibly some forms of Alzheimer's dementia.

How similar studies have performed: Laboratory and animal studies have shown that activating autophagy can reduce protein aggregates and improve cell function, but this approach has not yet been proven as a therapy in humans.

Where this research is happening

La Jolla, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.